Healthspan gap
Longevity and the Healthspan Gap
Lifespan is how long you live; healthspan is how long you live in good health. Medicine has become very good at stopping death and much less good at stopping decline, so lifespan grows faster than healthspan. Worldwide, people now spend on average about nine and a half years alive but not well. Treatments that slow decline itself barely exist, partly because nobody has agreed how to test them or who pays for them.
Lifespan extends faster than healthspan, so the years added are disproportionately years of managed illness.
Gradient 1.8 / 5 - weighed down most by the weakest enabler.
The average of these enablers is 2.3. The ramp runs at 1.8.
In the network
Also shaped by The Closing of the Planetary Envelope (3 shared enablers) · The Collapse of Shared Reality (1 shared enabler) · The Decoupling of Physical and Digital Life (2 shared enablers) · The Optimisation of Everything (3 shared enablers) · The Rebuild of the Physical Base (5 shared enablers) · The Redistribution of Power (1 shared enabler)
Enablers
| Enabler | Family | Weight | Maturity | Role |
|---|---|---|---|---|
| Brain-Computer Interfaces | technological | moderate | 1/5 | shared weakest link (with 1 other) |
| Longevity & Healthspan Interventions | technological | large | 1/5 | shared weakest link (with 1 other) |
| Assistive & Care Technology | technological | moderate | 2/5 | - |
| Regenerative Medicine | technological | large | 2/5 | - |
| Regulatory Clarity | structural | moderate | 2/5 | - |
| BioTech & Genomics | technological | large | 3/5 | - |
| Gene Editing | technological | large | 3/5 | - |
| Vaccine Platforms & Antimicrobials | technological | moderate | 3/5 | - |
| Nanotechnology | technological | moderate | 4/5 | - |
- Brain-Computer Interfacesshared weakest link (with 1 other)1/5
- Longevity & Healthspan Interventionsshared weakest link (with 1 other)1/5
- Assistive & Care Technologymoderate · technological2/5
- Regenerative Medicinelarge · technological2/5
- Regulatory Claritymoderate · structural2/5
- BioTech & Genomicslarge · technological3/5
- Gene Editinglarge · technological3/5
- Vaccine Platforms & Antimicrobialsmoderate · technological3/5
- Nanotechnologymoderate · technological4/5
The gradient behaves like a sticky rubber band: it is pulled hardest toward the weakest enabler. Marginal links are shown but do not pull. Everything above 1 is strength this ramp can use only in part until the weakest link moves.
What this pushes on, and what pushes on it
Bound by
Healthspan interventions and the incentives to develop them
Medicine is good at preventing death and poor at preventing decline. A drug that stops decline has no settled endpoint, trial design or payer.
Momentum. Medicine is good at preventing death and poor at preventing decline, and the incentives in drug development reinforce that asymmetry.
The four clocks
Four systems absorb this at four speeds. The distance between them is the adaptation gap.
Individuals
monthsBehaviour change is fast to start and rarely sustained; the outcome resolves over decades.
Companies
yearsYears - the pharmaceutical pipeline is long and currently pointed at disease rather than at decline.
Governments
decadesDecades. Pension and care liabilities are set by this gap and are being priced as though it will close.
The biosphere
not ours to setNot directly coupled.
Impacts by domain
Social & demographic
Global life expectancy reached 71.4 years in 2021, but healthy life expectancy stopped at 61.9 - a gap of 9.5 years that people now spend alive but not well (WHO, World Health Statistics 2024, May 2024).
Environmental
A global survey of 258 rivers across 104 countries found at least one pharmaceutical compound at unsafe concentrations in 25.7% of the 1,052 sites tested - the daily pill regimen of an ageing population, showing up downstream (Wilkinson et al., PNAS, February 2022).
Economic
The UK spends £7,500 a year on healthcare for the average person aged 85 or older, five times the £1,500 it spends on someone in their 30s or 40s (Office for Budget Responsibility, Fiscal Risks and Sustainability Report, July 2022).
Geopolitical
Over 60% of the EU's off-patent drug ingredients come from factories in India and China, and that dependency produced formal shortages of cardiovascular and antimicrobial medicines across 26 member states in 2023 (European Medicines Agency, October 2023).
What would prove this wrong
Healthy life expectancy rising at least as fast as total life expectancy across several countries for a decade.
Talin, B. (2026). Longevity and the Healthspan Gap. The Future Explorer, dataset v0.4.0 (2026-11-16). https://explorer.talin.digital/m/longevity-and-the-healthspan-gap/